Stockscreener 앱 받기
28.42
2.78%
0.77
시간 외 거래:
28.20
-0.22
-0.77%
Avalyn Pharma Inc 주식(AVLN)의 최신 뉴스
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Index - marketscreener.com
Avalyn Pharma Inc Actuals & Estimates (NASDAQ:AVLN) - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Value Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 3000E Growth Benchmark - marketscreener.com
AVLN Forecast — Price Target — Prediction for 2027 - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell Small Cap Completeness Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2500 Value Benchmark - marketscreener.com
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs - BioPharma Dive
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma (AVLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is Avalyn Pharma stock surging today? By Investing.com - Investing.com UK
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone By Investing.com - Investing.com Canada
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial By Investing.com - Investing.com Australia
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis - The Manila Times
Avalyn Pharma Ord Shs (Proposed) (AVLN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView
Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Avalyn Pharma Inc.: Target Price Consensus and Analysts Recommendations | AVLN | US05348Y1055 - marketscreener.com
Avalyn to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Avalyn, inhaled-therapy company for rare respiratory diseases, at Jefferies - Stock Titan
AVLN Initiated Coverage by Morgan Stanley -- Price Target Set at $53 - GuruFocus
AVLN Initiates Coverage by Guggenheim -- Price Target Announced at $80 - GuruFocus
1.17%
2.48%
자본화:
|
볼륨(24시간):